28319998,28319996,28328620,28327365,28318046,28318048,28318053,28329914,28323120,28329334,28332201,28323897,28323868[uid] - Search Results

1

Hoofnagle JH, Sherker AH. Hoofnagle JH, et al. Ann Intern Med. 2017 May 2;166(9):675-676. doi: 10.7326/M17-0567. Epub 2017 Mar 21. Ann Intern Med. 2017. PMID: 28319998 No abstract available.

2

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Falade-Nwulia O, et al. Ann Intern Med. 2017 May 2;166(9):637-648. doi: 10.7326/M16-2575. Epub 2017 Mar 21. Ann Intern Med. 2017. PMID: 28319996 Free PMC article. Review.

3

Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.

Ji F, Tian C, Li Z, Deng H, Nguyen MH. Ji F, et al. Eur J Gastroenterol Hepatol. 2017 Aug;29(8):977-979. doi: 10.1097/MEG.0000000000000873. Eur J Gastroenterol Hepatol. 2017. PMID: 28328620 No abstract available.

4

Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?

Mishra P, Chen M. Mishra P, et al. Gastroenterology. 2017 May;152(6):1270-1274. doi: 10.1053/j.gastro.2017.03.012. Epub 2017 Mar 19. Gastroenterology. 2017. PMID: 28327365 No abstract available.

5

Hepatitis C virus-induced CCL5 secretion from macrophages activates hepatic stellate cells.

Sasaki R, Devhare PB, Steele R, Ray R, Ray RB. Sasaki R, et al. Hepatology. 2017 Sep;66(3):746-757. doi: 10.1002/hep.29170. Epub 2017 Jul 18. Hepatology. 2017. PMID: 28318046 Free PMC article.

6

Hepatitis C treatment threshold in patients with decompensated liver disease.

Suraweera D, Saab S. Suraweera D, et al. Hepatology. 2017 Jun;65(6):1789-1791. doi: 10.1002/hep.29175. Epub 2017 May 3. Hepatology. 2017. PMID: 28318048 No abstract available.

7

Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.

Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, Lu CL. Chang FM, et al. Hepatology. 2017 Sep;66(3):896-907. doi: 10.1002/hep.29172. Epub 2017 May 8. Hepatology. 2017. PMID: 28318053

8

Ginsenoside Rg3 restores hepatitis C virus-induced aberrant mitochondrial dynamics and inhibits virus propagation.

Kim SJ, Jang JY, Kim EJ, Cho EK, Ahn DG, Kim C, Park HS, Jeong SW, Lee SH, Kim SG, Kim YS, Kim HS, Kim BS, Lee J, Siddiqui A. Kim SJ, et al. Hepatology. 2017 Sep;66(3):758-771. doi: 10.1002/hep.29177. Epub 2017 Aug 1. Hepatology. 2017. PMID: 28329914 Free PMC article.

9

How to eliminate HCV infection by antiviral treatment.

Martin NK, Vickerman P, Hickman M. Martin NK, et al. J Hepatol. 2017 Jul;67(1):5-6. doi: 10.1016/j.jhep.2017.03.008. Epub 2017 Mar 18. J Hepatol. 2017. PMID: 28323120 No abstract available.

10

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P. Wyles D, et al. J Infect Dis. 2017 Feb 15;215(4):599-605. doi: 10.1093/infdis/jiw597. J Infect Dis. 2017. PMID: 28329334 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page